ATE218350T1 - Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen - Google Patents

Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen

Info

Publication number
ATE218350T1
ATE218350T1 AT95914495T AT95914495T ATE218350T1 AT E218350 T1 ATE218350 T1 AT E218350T1 AT 95914495 T AT95914495 T AT 95914495T AT 95914495 T AT95914495 T AT 95914495T AT E218350 T1 ATE218350 T1 AT E218350T1
Authority
AT
Austria
Prior art keywords
treatment
acid derivatives
pct
dentures
loosened
Prior art date
Application number
AT95914495T
Other languages
English (en)
Inventor
Allen E Goodship
John Kenwright
Jonathan Green
Original Assignee
Novartis Erfind Verwalt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfind Verwalt Gmbh filed Critical Novartis Erfind Verwalt Gmbh
Application granted granted Critical
Publication of ATE218350T1 publication Critical patent/ATE218350T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Dental Preparations (AREA)
  • Prostheses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT95914495T 1994-05-04 1995-04-24 Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen ATE218350T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9408775A GB9408775D0 (en) 1994-05-04 1994-05-04 Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
PCT/IB1995/000288 WO1995030421A1 (en) 1994-05-04 1995-04-24 Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration

Publications (1)

Publication Number Publication Date
ATE218350T1 true ATE218350T1 (de) 2002-06-15

Family

ID=10754497

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914495T ATE218350T1 (de) 1994-05-04 1995-04-24 Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen

Country Status (18)

Country Link
US (1) US5965547A (de)
EP (1) EP0758241B1 (de)
JP (1) JPH09512816A (de)
AT (1) ATE218350T1 (de)
AU (1) AU693541B2 (de)
DE (1) DE69526937T2 (de)
DK (1) DK0758241T3 (de)
ES (1) ES2177642T3 (de)
FI (1) FI118590B (de)
GB (1) GB9408775D0 (de)
HU (1) HUT74984A (de)
IL (1) IL113566A (de)
NO (1) NO310057B1 (de)
NZ (1) NZ283430A (de)
PT (1) PT758241E (de)
TW (1) TW458779B (de)
WO (1) WO1995030421A1 (de)
ZA (1) ZA953537B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US6117856A (en) * 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
GB2336311A (en) * 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
US6137012A (en) 1998-10-13 2000-10-24 E. I. Du Pont De Nemours And Company Phosphole and diphosphole ligands for catalysis
CN1173704C (zh) 1998-12-04 2004-11-03 罗什诊断学股份有限公司 伊班卓酸盐在促进内假体骨整合中的应用
WO2000047214A1 (en) * 1999-02-09 2000-08-17 Sloan-Kettering Institute For Cancer Research Anti-resorptive bone cements and allogeneic, autografic, and xenografic bone grafts
WO2001008690A1 (fr) * 1999-08-02 2001-02-08 Toray Industries, Inc. Stabilisateurs d'insertion pour implants
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
EP1591122B1 (de) 2000-06-20 2012-09-26 Novartis AG Methode zur Verabreichung von Biphosphonaten
DK1296689T3 (da) * 2000-06-20 2005-11-28 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater
AU2001287260A1 (en) * 2000-07-12 2002-01-21 Ecole Polytechnique Federale De Lausanne (Epfl) Active biocoating for bone implant
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
BR0308901A (pt) * 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
TWI344367B (en) * 2002-09-16 2011-07-01 Novartis Ag Use of zoledronic acid or a pharmaceutically acceptable salt or hydrate thereof in the preparation of a medicament for the treatment of osteoporosis post hip fracture
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
WO2008059060A1 (en) * 2006-11-17 2008-05-22 Besins Healthcare Liquid pharmaceutical compositions comprising a bisphosphonate compound
EP1958649A1 (de) * 2007-02-14 2008-08-20 Graftys Injizierbarer Kalzium-Phospat-Zement zur Freisetzung eines Knochenschwund-Inhibitors
US20100144679A1 (en) * 2007-03-21 2010-06-10 Duke University Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
WO2008152518A2 (en) * 2007-05-16 2008-12-18 Actavis Group Ptc Ehf Process for the preparation of risedronic acid or risedronate sodium
DK2473172T3 (en) 2009-09-01 2015-06-15 Univ Duke BISPHOSPHONATSAMMENSÆTNINGER and Methods for treating congestive heart failure
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
WO2013074587A1 (en) 2011-11-16 2013-05-23 Duke University Bishophonate compositions and methods for treating and/or reducing cardiac dysfunction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
ES2038692T4 (es) * 1986-11-21 2012-02-10 Novartis Ag Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos.
JPH05163150A (ja) * 1991-05-13 1993-06-29 E R Squibb & Sons Inc アテローム性動脈硬化症の抑制・治療剤
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices

Also Published As

Publication number Publication date
EP0758241B1 (de) 2002-06-05
EP0758241A1 (de) 1997-02-19
DE69526937T2 (de) 2003-01-02
NO964486D0 (no) 1996-10-22
HUT74984A (en) 1997-03-28
JPH09512816A (ja) 1997-12-22
ZA953537B (en) 1995-11-06
NO964486L (no) 1996-10-22
FI118590B (fi) 2008-01-15
FI964332L (fi) 1996-10-28
ES2177642T3 (es) 2002-12-16
HU9603042D0 (en) 1997-01-28
WO1995030421A1 (en) 1995-11-16
DE69526937D1 (de) 2002-07-11
US5965547A (en) 1999-10-12
NZ283430A (en) 2000-06-23
DK0758241T3 (da) 2002-09-23
PT758241E (pt) 2002-10-31
NO310057B1 (no) 2001-05-14
IL113566A0 (en) 1995-08-31
TW458779B (en) 2001-10-11
AU2146695A (en) 1995-11-29
FI964332A0 (fi) 1996-10-28
AU693541B2 (en) 1998-07-02
IL113566A (en) 2002-05-23
GB9408775D0 (en) 1994-06-22

Similar Documents

Publication Publication Date Title
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69400435D1 (de) Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson-syndromen
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
ATE216877T1 (de) Verwendung von nsaids zur behandlung von plattenepithelkarzinom der mundhöhle und kehlkopf
ATE237633T1 (de) Analogen des keratinozytenwachstumfaktors
ATE217197T1 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
ATE252897T1 (de) Verwendung von p-aminophenolderivaten zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von neurodegenerativen erkrankungen
DE69927147D1 (de) Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE289808T1 (de) Caroteinoid-nicotinamid-zink zusammensetzungen und verfahren zur behandlung unter verwendung derselben
DE59508961D1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
NZ331953A (en) Benzopyran derivatives having leukotriene-antagonistic action
ATE232094T1 (de) Verwendung eines 5ht2 rezeptor-antagonisten zur behandlung von schlafapnoe
BG105275A (en) Tan-1057 derivatives
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
ATE247474T1 (de) Verwendung von inosittriphosphat zur herstellung von arzneimitteln
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
ATE213634T1 (de) Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee